Shanghai-based VelaVigo has been busy. The biotech granted Avenzo Therapeutics ex-China rights to a Nectin4xTROP2 bispecific antibody-drug conjugate in November, netting up to $50 million in ...

So, here we are, launching our fourth edition of Fierce Biotech's layoff tracker. As always, if you know of a layoff occurring at a biotech, please reach out to the Fierce Biotech editorial team ...

Biotech stocks are in the eye of the storm as the world recovers from the global pandemic. Government institutions and professional traders are banking on biotech stocks to continually develop a ...

Meghana Keshavan covers biotech and contributes to The Readout newsletter. Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Join biotech commentators Daphne Zohar, Josh Schimmer, and Brad Loncar for a weekly discussion of all things biotech. From emerging trends and investment opportunities to the challenges facing the ...

Celebrating 10 years, we are a Boston-based change management and strategy consultant firm working… Boston, MA – VPNE Parking Solutions, LLC, a leader in the parking, transportation, hospitali ...

half-day interactive event designed to equip… The Future of Bay Area Biotech: Searching For Answers Join the San Francisco Business Times for our annual 40 Under 40 awards event celebrating ...

Fidelity Advisor Biotechnology Fund earns an Average Process Pillar rating. The most notable contributor to the rating is its parent firm's excellent long-term risk-adjusted performance ...

The Chinese biotech industry has grown rapidly to become a major hub of research. However, as US-China trade relations continue to deteriorate, Ben Hargreaves asks whether this could stunt ...

wallpaper, and education, as well as consumer office, stationery and craft papers to retailers, small business, personal use, and educational applications; and healthcare and other products ...

Apr. 22, 2025 — Asymmetric interactions between molecules may serve as a stabilizing factor for biological systems. A new model reveals this regulatory role of non-reciprocity. The scientists ...

In this article, we take a look at seven biotech companies with clinical drug candidates on a quest to win regulatory approval to treat hepatitis B. Chronic HBV infection is the leading cause of ...